References
- Pace D. Leishmanasis. J Infect. 2014; 69(1):10-18.
- Firooz A, Mortazavi H, Khamesipour A, Ghiasi M, Abedini R, Balighi K,
et al. Old World cutaneous leishmaniasis in Iran: clinical variants
and treatments. J Dermatolog Treat. 2020; 8:1-11.
- Van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J.
Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect.
2014;20(4):286-299.
- Liese J, Schleicher U, Bogdan C. The innate immune response against
Leishmania parasites. Immunobiology. 2008;213(3-4):377-387.
- Català A, Roé E, Dalmau J, Pomar V, Muñoz C, Yelamos O, et
al. Anti-tumour necrosis factor-induced visceral and cutaneous
leishmaniasis: case report and review of the literature. Dermatology.
2015; 230: 204–207.
- Chichester AV, dos Reis AL, Castanheira AT, da Silva Nascimento CV,
Biasi BH, Lodi VJ, et al. American Cutaneous Leishmaniasis: A
Pleomorphic Disease with Unusual Clinical Presentations-Report of
Three Cases. Int Arch Med. 2020 Jan 19;13. doi: 10.3823/2617
- Zandieh A, Zandieh B, Dastgheib L. Dissemination of localized
cutaneous leishmaniasis in an organ transplant recipient: case report
and literature review. Int J Dermatol. 2013;52(1):59-62.
- Golino A, Duncan JM, Zeluff B, DePriest J, McAllister HA, Radovancevic
B, et al. Leishmaniasis in a heart transplant patient. J Heart Lung
Transplant. 1992; 11(4 Pt 1):820-823.
- Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V.
Reactivation of dormant cutaneous Leishmania infection in a kidney
transplant patient. J Cutan Pathol. 2006 Oct;33(10):701-704.
- Jafari S, Hajiabdolbaghi M, Mohebali M, Hajjaran H, Hashemian H.
Disseminated leishmaniasis caused by Leishmania tropica in
HIV-positive patients in the Islamic Republic of Iran. Eastern
Mediterranean Health Journal. 2010;16(3):340-343
- Alcover MM, Rocamora V, Guillén MC, Berenguer D, Cuadrado M, Riera C,
et al. Case report: diffuse cutaneous leishmaniasis by Leishmania
infantum in a patient undergoing immunosuppressive therapy: risk
status in an endemic Mediterranean area. Am J Trop Med Hyg.
2018;98(5):1313-1316.
- Tuon FF, Sabbaga Amato V, Floeter‐Winter LM, De Andrade Zampieri R,
Amato Neto V, Siqueira França FO, et al. Cutaneous leishmaniasis
reactivation 2 years after treatment caused by systemic
corticosteroids–first report. Int J Dermatol. 2007;46(6):628-630.
- Darcis G, Van der Auwera G, Giot JB, Hayette MP, Tassin F, Estrada JA,
et al. Recurrence of visceral and muco-cutaneous leishmaniasis in a
patient under immunosuppressive therapy. BMC Infect Dis. 2017 Dec
1;17(1):478.
- Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F,
Nilforoushzadeh M, et al. Intralesional injection of 2% zinc sulfate
solution in the treatment of acute Old World cutaneous leishmaniasis:
a randomized, double-blind, controlled clinical trial. J Drug
Dermatol. 2005; 4:73–77.
- Zerehsaz F, Salmanpour R, Handjani F, Ardehali S, Panjehshahin MR,
Tabei SZ, et al. A double-blind randomized clinical trial of a topical
herbal extract (Z-HE) vs. systemic meglumine antimoniate for the
treatment of cutaneous leishmaniasis in Iran. Int J Dermatol. 1999;
38:610–612.